Kivizidiale (Timolol, Travoprost)

Timolol reduces the production of aqueous humor by blocking beta‑adrenergic receptors in the eye, while travoprost increases uveoscleral outflow by acting as a prostaglandin F2α analog. The dual mechanism provides a complementary pressure‑lowering effect.

The prescribed dose is determined by the treating eye‑care professional. Typically, one drop is instilled in the affected eye(s) once daily, but the exact regimen, including any adjustments, should follow the prescriber’s instructions.

Safety data for timolol/travoprost in pregnancy and lactation are limited. The product should only be used when the potential benefit justifies any possible risk to the fetus or infant, and decisions should be made by a qualified healthcare provider.

Enquiries can be submitted on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy agents such as latanoprost or timolol alone, Kivizidiale offers a combined mechanism that often achieves greater intra‑ocular pressure reduction. This can simplify treatment regimens by reducing the need for multiple separate drops.

Store the eye‑drops at room temperature, preferably below 25 °C. Keep the bottle in its original packaging, protect it from direct light and moisture, and ensure the cap is tightly closed when not in use.

The patient should wash hands, tilt the head back, and gently pull down the lower eyelid to create a small pocket. One drop is placed into the conjunctival sac, avoiding contact between the tip and the eye or eyelashes. The eye should be closed gently for a few seconds to aid absorption.

Serious adverse events include severe allergic reactions, sudden loss of vision, marked eye pain, paradoxical rise in intra‑ocular pressure, systemic bradycardia or hypotension, and worsening of asthma or COPD. Patients should seek immediate medical attention if any of these occur.

Kivizidiale is contraindicated in patients with known hypersensitivity to timolol, travoprost, or any excipients, and in those with severe sinus bradycardia, advanced heart block, or uncontrolled asthma. Caution is also advised for individuals with severe chronic obstructive pulmonary disease.